Johnson & Johnson Orthopaedics, Inc. v. Minnesota Mining & Manufacturing Co.

715 F. Supp. 110, 1989 U.S. Dist. LEXIS 7943, 1989 WL 76494
CourtDistrict Court, D. Delaware
DecidedJuly 13, 1989
DocketCiv. A. 89-247-JJF
StatusPublished
Cited by2 cases

This text of 715 F. Supp. 110 (Johnson & Johnson Orthopaedics, Inc. v. Minnesota Mining & Manufacturing Co.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Johnson & Johnson Orthopaedics, Inc. v. Minnesota Mining & Manufacturing Co., 715 F. Supp. 110, 1989 U.S. Dist. LEXIS 7943, 1989 WL 76494 (D. Del. 1989).

Opinion

OPINION

FARNAN, District Judge.

This case is presently before the Court on defendant Minnesota Mining and Manufacturing Company’s (“3M”) motion for a temporary restraining order (“TRO”). Because the Court concludes that 3M has failed to establish irreparable injury, the Court will deny 3M’s motion.

FACTUAL AND PROCEDURAL BACKGROUND

Plaintiff Johnson & Johnson Orthopaed-ics, Inc. (“J & J”) is the owner of all right and title to U.S. Patent No. 4,433,680 (“the ’680 patent”), which relates to an improved polyurethane orthopaedic casting bandage used to form orthopaedic casts. Of particular relevance is the use of a dimorpholinodiethylether (“DMDEE”) catalyst.

On March 1, 1985, J & J and 3M entered into a license agreement whereby J & J granted a nonexclusive license to 3M to manufacture, use, and sell synthetic casting bandages falling within the scope of claims of the ’680 patent. In consideration therefore, 3M agreed to pay calculated royalties. The license agreement further provides that upon default by either party, the other party shall give written notice, and unless the default is cured within two months after notice is given, the party giving notice may give further written notice terminating the license agreement.

On May 16, 1989, J & J filed a complaint in this Court alleging breach of contract and seeking declaratory judgments of contract rights and infringement. J & J alleges that 1) since the beginning of 1987 through the present, 3M has been manufacturing and selling orthopaedic bandages using a so-called “MEMPE” catalyst; 2) these bandages are within the scope of the claims of the ’680 patent; 3) and 3M has materially breached the terms of the license agreement by failing to pay royalties with respect to these bandages. On June 23, 1989, 3M filed a motion for summary judgment or, in the alternative, for a preliminary injunction to enjoin J & J from issuing a notice of termination of the license agreement.

On July 6, 1989, 3M filed the instant motion for a TRO, asserting that it believes J & J is likely to issue a notice of termination of the license agreement between the parties on July 18, 1989. In its motion, 3M seeks to restrain J & J from attempting to terminate the license agreement and to toll the time under the license agreement for 3M 'to cure any default. 3M contends that its motion simply seeks to preserve the “status quo” between the parties under the license agreement pending a final adjudication on the merits.

STANDARD FOR A TRO MOTION

Generally, the standards for granting a preliminary injunction and issuing a TRO are the same, the difference being solely *112 one of duration of the order. See Tootsie Roll Industries, Inc. v. Sathers, Inc., 666 F.Supp. 655, 658 (D.Del.1987). Although courts have phrased the appropriate standard in a seemingly endless variety of ways, the relevant factors to be considered and balanced by the Court are essentially the same: 1) reasonable likelihood of success on the merits; 2) irreparable harm to the moving party in the absence of relief; 3) harm to the other parties if relief is granted; and 4) the public interest. Compare Fechter v. HMW Industries, Inc., 879 F.2d 1111, 1116-17 (3d Cir.1989) with Hy-britech, Inc. v. Abbott Laboratories, 849 F.2d 1446, 1451 (Fed.Cir.1988). 1

Although irreparable injury is only one of four “factors,” a moving party’s inability to establish irreparable injury is, alone, fatal to the motion. Phillips Petroleum Co. v. United States Steel Corp., 616 F.Supp. 335, 337-38 (D.Del.1985). In addition, “irreparable injury” is pregnant with meaning. The harm must be “imminent,” Tree Tavern Products, Inc. v. Conagra, Inc., 640 F.Supp. 1263, 1272 (D.Del.1986); not otherwise compensable by money damages, Frank’s GMC Truck Center, Inc. v. GMC, 847 F.2d 100, 102-03 (3d Cir.1988); “actual,” Phillips, 616 F.Supp. at 338; and “sufficiently peculiar,” Coca-Cola Bottling of Elizabethtown v. Coca-Cola Co., 668 F.Supp. 906, 910 (D.Del.1987). The moving party must make a “clear showing of immediate irreparable injury” or a “presently existing actual threat,” but an injunction will not issue merely to assuage the fears of the movant. Continental Group, Inc. v. Amoco Chem. Corp., 614 F.2d 351, 359 (3d Cir.1980). More succinctly put, “the injury contemplated must be real, not fancied; actual, not prospective; and threatened, not imagined.” Cordis Corp. v. Medtronic Inc., 2 U.S.P.Q.2d 1845, 1847 (D.Minn.1986), aff’d, 835 F.2d 859 (Fed.Cir.1987).

DISCUSSION

The Court need only focus on the irreparable injury factor in its analysis of the instant motion. 3M has identified four distinct ways in which it claims it will be irreparably injured if a TRO does not issue. The Court will address each alleged injury.

First, 3M contends that without the TRO it will “immediately lose its only strategic alternative catalyst supply.” Specifically, 3M argues that although it currently uses its own patented MEMPE catalyst, the DMDEE catalyst is an important strategic contingency which 3M cannot afford to lose if J & J terminates the license agreement. 3M argues that there exists a “real and constant danger” of a chemical accident at its MEMPE manufacturing plant and that DMDEE is the only other catalyst currently available to 3M. As the leading supplier of synthetic orthopaedic casting tapes in this country, 3M argues that it would incur a severe competitive disadvantage were it not able to switch to the DMDEE catalyst at any time.

J & J deems this alleged harm speculative and prospective. The Court agrees. Should J & J terminate the license agreement, 3M’s use of the DMDEE catalyst *113 would infringe claims under the ’680 patent. But 3M has represented that DMDEE is only an alternative, contingent catalyst to MEMPE. Although the Court recognizes that 3M may find itself in a risky position should it be unable to fall back on the DMDEE catalyst in the event of a MEMPE plant shutdown, such a threat is simply too speculative to warrant the relief that 3M seeks. The harm claimed by 3M is not imminent and actual, but rather contingent and remote. 3M has only demonstrated its business fears and not a “presently existing actual threat.”

Second, 3M contends that if the Court fails to restrain J & J from terminating the license agreement, 3M’s customers will “immediately be exposed to litigation by J & J” for infringement. J & J counters that its suit against 3M bars subsequent suits against 3M’s customers, that J & J has no interest in or intention of suing 3M’s customers, and that again the alleged harm is purely speculative.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
715 F. Supp. 110, 1989 U.S. Dist. LEXIS 7943, 1989 WL 76494, Counsel Stack Legal Research, https://law.counselstack.com/opinion/johnson-johnson-orthopaedics-inc-v-minnesota-mining-manufacturing-ded-1989.